The Value of Residual Volume/Total Lung Capacity as an Indicator for Predicting Postoperative Lung Function in Non-Small Lung Cancer
by
, ,
Oh-Beom Kwon
1,†
,
Chang-Dong Yeo
1,†,
Hwa-Young Lee
2,
Hye-Seon Kang
1,
Sung-Kyoung Kim
1,
Ju-Sang Kim
1,
Chan-Kwon Park
1,
Sang-Haak Lee
1,3,
Seung-Joon Kim
1,4,5 and
Jin-Woo Kim
1,* 1
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
2
Division of Allergy, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
3
Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
4
Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul 06591, Korea
5
Postech-Catholic Biomedical Engineering Institute, Songeui Multiplex Hall, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
†
O.-B.K. and C.-D.Y. contributed equally to this study.
J. Clin. Med. 2021, 10(18), 4159; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10184159
Submission received: 23 August 2021
/
Revised: 9 September 2021
/
Accepted: 13 September 2021
/
Published: 15 September 2021
(This article belongs to the Section Pulmonology)
Abstract
:Chronic obstructive pulmonary disease (COPD) is one of the most frequently occurring concomitant diseases in patients with non-small cell lung cancer (NSCLC). It is characterized by small airways and the hyperinflation of the lung. Patients with hyperinflated lung tend to have more reserved lung function than conventionally predicted after lung cancer surgery. The aim of this study was to identify other indicators in predicting postoperative lung function after lung resection for lung cancer. Patients with NSCLC who underwent curative lobectomy with mediastinal lymph node dissection from 2017 to 2019 were included. Predicted postoperative FEV1 (ppoFEV1) was calculated using the formula: preoperative FEV1 × (19 segments-the number of segments to be removed) ÷ 19. The difference between the measured postoperative FEV1 and ppoFEV1 was defined as an outcome. Patients were categorized into two groups: preserved FEV1 if the difference was positive and non-preserved FEV1, if otherwise. In total, 238 patients were included: 74 (31.1%) in the FEV1 non-preserved group and 164 (68.9%) in the FEV1 preserved group. The proportion of preoperative residual volume (RV)/total lung capacity (TLC) ≥ 40% in the FEV1 non-preserved group (21.4%) was lower than in the preserved group (36.1%) (p = 0.03). In logistic regression analysis, preoperative RV/TLC ≥ 40% was related to postoperative FEV1 preservation. (adjusted OR, 2.02, p = 0.041). Linear regression analysis suggested that preoperative RV/TLC was positively correlated with a significant difference. (p = 0.004) Preoperative RV/TLC ≥ 40% was an independent predictor of preserved lung function in patients undergoing curative lobectomy with mediastinal lymph node dissection. Preoperative RV/TLC is positively correlated with postoperative lung function.
1. Introduction
Lung cancer can be classified into two major classes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [1]. Surgical resection is the standard treatment for early stage NSCLC [2]. Chronic obstructive pulmonary disease (COPD) is an important risk factor for lung cancer and is one of the most frequently occurring concomitant diseases in patients with lung cancer [3,4]. COPD is characterized by chronic airflow limitation due to small airways (obstructive bronchiolitis) and parenchymal destruction (emphysema) [5]. Lung volume reduction surgery (LVRS) is an accepted therapeutic option for patients with severe emphysema to relieve symptoms such as dyspnea and increased work of breathing. Spiration valve system (SVS) is a bronchoscopic lung volume reduction therapy, and it results in significant improvements in postoperative forced expiratory volume in one second (FEV1) and symptoms [6,7,8]. In order to predict postoperative lung function, the results of these studies indicating that reducing lung volume improves postoperative lung function should be considered.
Patients with COPD are known to manifest worse survival outcomes than patients without COPD in NSCLC treated with surgical resection [9]. Nevertheless, with the exception of surgical resection, no other treatment options are available to most of the patients with early stage NSCLC with COPD [10]. Since postoperative lung function is related to postoperative complications, postoperative changes in quality of life (QOL), and perioperative mortality, predicting postoperative lung function is crucial, and the treatment strategy should be established accordingly.
Predicted postoperative FEV1 (ppoFEV1) was used to predict postoperative pulmonary function for the assessment of perioperative risk. The ppoFEV1 can be calculated using a formula based on the number of resected segments [11,12]. However, COPD patients who underwent surgery had a relatively more preserved postoperative FEV1 than non-COPD patients did [13]. Previous studies reported that non-squamous cell histology, upper lobe resection, and current smoking status were related to poor postoperative outcomes [14,15,16,17]. These factors have insufficient accuracy in predicting postoperative lung function, and there is no accurate method available to predict postoperative lung function. This suggests the need for accurate clinical prognostic indicators. The objective of this study was to identify other prognostic indicators that can complement ppoFEV1 to increase the prediction accuracy of postoperative lung function.
2. Materials and Methods
2.1. Study Population
A total of 238 patients with lung cancer who underwent curative lobectomy with mediastinal lymph node dissection at seven hospitals in the Catholic University of Korea (Seoul St. Mary’s Hospital, Incheon St. Mary’s Hospital, Yeouido St. Mary’s Hospital, Eunpyeong St. Mary’s Hospital, Bucheon St. Mary’s Hospital, St. Vincent’s Hospital, and Uijeongbu St. Mary’s Hospital) from 2017 to 2019 were included. The inclusion criteria were pathologically confirmed primary NSCLC, no relapse up to 12 months after surgery, and R0 resection. Relapse was defined based on radiological or histological evidence of cancer within 12 months after treatment [18,19]. The study included 238 patients who underwent pulmonary function test (PFT) during the evaluation period (6 ± 3 months). Incomplete records of 62 patients were detected in the second evaluation period (12 ± 3 months). We analyzed the PFT data of 176 patients during the second evaluation period. This study was approved by the Institutional Review Board (IRB) of the Catholic University of Korea. (IRB: XC20RIDI0137). The requirement for informed consent was waived due to the retrospective nature of the study.
2.2. Data and Outcome Definition
Demographic data including age and gender, Eastern Cooperative Oncology Group (ECOG) Performance Scale, histologic features, smoking history, post-operative tumor stage according to the eighth edition of the tumor–node–metastasis (TNM) classification [20], cancer location, and PFT results were collected. FEV1, FEV1/forced vital capacity (FVC), the diffusing capacity of the lung for carbon monoxide (DLCO), and the residual volume (RV)/total lung capacity (TLC) were measured three times: before surgery, 6 ± 3 months (abbreviated as 6 months for convenience) after surgery, and 12 ± 3 months (abbreviated as 12 months) after surgery. Based on smoking history, the patients were grouped into never smokers if they never smoked or if they had smoked less than 100 cigarettes in their lifetime, and ever smokers if they had smoked at least 100 cigarettes in their lifetime [18,21]. PFT was performed in accordance with the American Thoracic Society/European Respiratory Society standardization guidelines. In order to compare the postoperative lung function with ppoFEV1, ppoFEV1 was calculated using the formula: preoperative FEV1 × (19 segments-the number of segments to be removed) ÷ 19. The number of segments for each lobe was: right upper lobe, three; right middle lobe, two; right lower lobe, five; left upper lobe, five; and left lower lobe, four [11,12]. Difference was defined as the postoperative FEV1 minus ppoFEV1. Outcome was defined as preserved FEV1 if the difference was positive and non-preserved FEV1 if the difference was negative, and the patients were categorized accordingly.
2.3. Predictive Factors
If lung cancer was located in the right upper lung (RUL) or the left upper lung (LUL), it was categorized as both upper lungs (BUL). Preoperative FEV1 ≥ 80%, FEV1/FVC ≥ 70%, and DLCO ≥ 80% were used as cut-off values to categorize preoperative lung function and to analyze factors associated with postoperative lung function. Preoperative RV/TLC ≥ 40% was used to represent pulmonary hyperinflation [22].
2.4. Statistical Analysis
All statistical analyses were performed using R software, version 4.0.5. (R Foundation for Statistical Computing, Vienna, Austria) Continuous variables are presented as means with standard deviation. Categorical variables are expressed as numbers with percentages. Patients were categorized into two groups: FEV1 preserved and FEV1 non-preserved. The unpaired Student’s t test was used for the comparison of continuous variables between the two groups. The Chi-squared test was performed for the analysis of categorical variables. Univariate and multivariate logistic regression analyses were used to determine the factors associated with preserved FEV1 at 6 months after surgery. All variables with p < 0.2 in the univariate analysis were included in the multivariate analysis. The odds ratio (OR) and a 95% confidence interval (CI) were computed for each category. Univariate linear regression was performed to assess the individual effects of the pulmonary lung function variables and hyperinflation on FEV1 after surgery. All of the variables were entered into multiple linear regression analysis. P values less than 0.05 were considered statistically significant for all analyses.
3. Results
3.1. Overall Patient Characteristics
A total of 238 patients with primary lung cancer who received a curative lobectomy with mediastinal lymph node dissection and did not relapse up to 12 months after surgery were included. The patient characteristics are presented in Table 1. The mean age of the patients was 66.7 years, and the majority of the patients (60.5%) were male. Most of the patients had an ECOG performance scale of 0–1 (99.2%), and adenocarcinoma was the dominant histologic feature (69.7%). In regard to smoking status, the proportions of patients who were never smokers and ever smokers were 39.5% and 60.5%, respectively. Stage I was the most common stage (66.8%), and the LUL was the most common lung cancer location (29.4%). The second most common lung cancer site was the RUL (26.9%). The preoperative PFT results were: FEV1 97.8 ± 21.5 %; FEV1/FVC 73.2 ± 9.5 %; DLCO 88.2 ± 19.1%; and RV/TLC 35.9 ± 8.7%.
3.2. Comparison of FEV1 Non-Preserved and Preserved Groups
A comparison of the two groups presented in Table 2 reveals that 74 patients (31.1%) had non-preserved FEV1, while 164 (68.9%) had preserved FEV1. The mean age (p = 0.44), sex distribution (p = 0.73), ECOG performance scale (p = 0.56), histologic features (p = 0.09), smoking status (p = 0.52), stage (p = 0.64), and lung cancer location (p = 0.16) did not differ between the two groups. The proportion of preoperative RV/TLC ≥ 40% in the FEV1 non-preserved group (21.4%) was lower than in the preserved group (36.1%) (p = 0.03).
3.3. Factors Associated with Preserved Postoperative FEV1
The results of the logistic regression analysis identifying the factors associated with postoperative FEV1 preservation are presented in Table 3. Histologic features (unadjusted OR 1.84, 95% CI 0.90–3.73, p = 0.093), location of lung cancer (unadjusted OR 0.67, 95% CI 0.38–1.17, p = 0.157), and preoperative RV/TLC ≥ 40% (unadjusted OR 2.11, 95% CI 1.09–4.06, p = 0.026) had a p value less than 0.2 in the univariate analysis. Only preoperative RV//TLC ≥ 40% (adjusted OR 2.02, 95% CI 1.03–3.97, p = 0.041) remained statistically significant in multivariate analysis.
3.4. Correlation of Differences with Preoperative PFT Parameters and Postoperative FEV1
In the univariate linear regression analysis (Table 4), preoperative FEV1 (p = 0.032), FEV1/FVC (p = 0.020) showed a significant negative correlation, and RV/TLC (p = 0.001) showed a significant positive correlation with a difference. The scatter plot for difference and RV/TLC is presented in Figure 1a. The scatter plot for FEV1/FVC is provided in Figure 1b. In the multiple linear regression analysis (Table 4), RV/TLC was the only significant variable that was positively correlated with statistically significant difference (p = 0.004).
4. Discussion
In this study, we found that RV/TLC was a prognostic indicator for predicting postoperative lung function by comparing the postoperative measured FEV1 with the conventional method of prediction and that it can be calculated using a simple formula [11]. Further, only the correlation between RV/TLC and postoperative lung function showed statistical significance, while the correlation with other conventional variables such as preoperative FEV1, FEV1/FVC, and DLCO were not statistically significant. These results suggest that traditional prediction methods are insufficient and that hyperinflation, which can be assessed by RV/TLC, is an important factor to predict postoperative lung function. Since RV/TLC is correlated with postoperative lung functions, it can be treated as an treatment plan indicator.
Preoperative RV/TLC ≥ 40% is associated with more frequent exacerbations and is an independent risk factor for all-cause mortality in COPD [23]. In order to compare the extent of postoperative FEV1 changes in a hyperinflated lung with that of the normal lung, RV/TLC ≥ 40% was considered as a prognostic indicator. Patients with preoperative RV/TLC ≥ 40% had reserved lung function that was greater than predicted at 6 months after surgery. Patients with emphysema manifest low preoperative FEV1 and might be considered surgically contraindicated. However, previous studies have shown that surgery can improve postoperative lung function [24]. Surgery reduced hyperinflation, which increased the elastic recoil and global inspiratory muscle strength, which resulted in symptom improvement and reserved lung function [6].
In our study, a total of 55.3% of the patient population had lung cancer involving the upper lobe (29.4% in LUL, 26.9% in RUL). Previous studies have shown that volume loss was larger in upper lobectomy than in lower lobectomy, and lower lobectomy led to better postoperative compensation [16]. Upper lobectomy leads to an upward displacement of the diaphragm and the remaining lung, resulting in bronchial kinking and obstruction and worse postoperative lung function [25,26]. When cancer was located at either of the upper lobes, the OR was 0.67 in the univariate analysis and was 0.68 for the multivariate analysis, which was consistent with previous studies. However, the sample size was not large enough to reach statistical significance (Table 3).
Surgery is considered as the first choice of treatment for lung cancer and is associated with the lowest mortality rate compared with other modalities [2,27]. However, patients with comorbidities tend to manifest higher postoperative morbidity and mortality after surgery [28,29]. The prevalence of COPD in patients with lung cancer was 40–70%. Due to the increased prevalence of COPD and lung cancer, the number of surgeries involving patients with reduced lung function also increased [3,4,27]. Surgical resection in these patients with lower FEV1 might lead to respiratory failure and therefore requires careful evaluation of postoperative lung function. Since postoperative function is predicted by the proportion of resected lobes, a low preoperative FEV1 might lead to limited resection, which can result in poor survival rates [14].
However, resection surgery can improve lung function in patients with COPD by reducing pulmonary hyperinflation [6,7,14]. To evaluate lung function, FEV1/FVC is used to measure airway obstruction, and RV/TLC is used to measure lung hyperinflation [22]. COPD is an obstructive lung disease that results in low FEV1/FVC, whereas emphysematous lung is hyperinflated, which results in high RV/TLC. FEV1/FVC is usually used to estimate the severity of COPD because it represents the degree of airway obstruction. In this study, we measured preoperative RV/TLC ≥ 40% to represent hyperinflation [22]. Patients with preoperative RV/TLC ≥ 40% had reserved lung function compared to ppoFEV1, which implies that patients deemed inoperable with low preoperative FEV1 due to a hyperinflated lung might be considered operable. Therefore, RV/TLC calculation can increase the accuracy of predicting postoperative lung function.
The study has several limitations, but these were trivial due to the following reasons: It was a short-term study lasting up to 6 months after surgery, and the had a bias due to missing data. We also evaluated 12-month data, but they was not fully analyzed due to missing values (data not shown). In our study, postoperative FEV1 was compared with ppoFEV1, which was calculated using the formula. A ventilation–perfusion scan can predict postoperative FEV1 more accurately than the formula can [30]. However, ventilation–perfusion scan data were not available in this study. Future studies should compare postoperative measured FEV1 with ppoFEV1 using ventilation–perfusion scan. The method of surgery (open thoracotomy or video-assisted thoracoscopic surgery) was not distinguished. However, video-assisted thoracoscopic surgery was performed unless contraindications existed at the hospitals, as previously indicated. Patients received adjuvant therapies, including chemotherapy and radiotherapy, according to the National Comprehensive Cancer Network (NCCN) guidelines, but the type of adjuvant therapy was not considered as a factor in this study [31]. This factor can affect post-operative lung function and therefore is another limitation of this study, suggesting the need for further studies.
5. Conclusions
Preoperative RV/TLC ≥ 40% was an independent predictor of reserved lung function in patients undergoing curative lobectomy with mediastinal lymph node dissection, and it was positively correlated with postoperative FEV1. Further large-scale studies are required to predict postoperative lung function and the prognosis of patients after surgery.
Author Contributions
Conceptualization, O.-B.K., C.-D.Y., H.-S.K., S.-J.K. and J.-W.K.; methodology, C.-K.P., H.-Y.L. and S.-H.L.; software, O.-B.K. and C.-D.Y.; validation, S.-K.K. and J.-W.K.; formal analysis, O.-B.K. and C.-D.Y.; investigation, C.-K.P. and S.-H.L.; resources, C.-D.Y. and H.-S.K.; data curation, H.-Y.L.; writing—original draft preparation, O.-B.K. and C.-D.Y.; writing—review and editing, O.-B.K. and C.-D.Y.; visualization, H.-S.K., S.-K.K. and J.-S.K.; supervision, C.-D.Y. and J.-W.K.; project administration, C.-D.Y. and J.-W.K. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by The Catholic University of Korea, Eunpyeong St. Mary’s Hospital Research Institute of Medical Science.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of the Catholic University of Korea. (XC20RIDI0137).
Informed Consent Statement
Patient consent was waived due to the retrospective nature of the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Travis, W.D.; Brambilla, E.; Nicholson, A.G.; Yatabe, Y.; Austin, J.H.M.; Beasley, M.B.; Chirieac, L.R.; Dacic, S.; Duhig, E.; Flieder, D.B.; et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. 2015, 10, 1243–1260. [Google Scholar] [CrossRef] [Green Version]
- Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.R.; Bharat, A.; Bruno, D.S.; Chang, J.Y.; Chirieac, L.R.; D’Amico, T.A.; et al. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021. J. Natl. Compr. Cancer Netw. 2021, 19, 254–266. [Google Scholar] [CrossRef]
- Young, R.P.; Hopkins, R.J.; Christmas, T.; Black, P.N.; Metcalf, P.; Gamble, G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 2009, 34, 380–386. [Google Scholar] [CrossRef] [Green Version]
- Moro-Sibilot, D.; Aubert, A.; Diab, S.; Lantuejoul, S.; Fourneret, P.; Brambilla, E.; Brambilla, C.; Brichon, P.Y. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur. Respir. J. 2005, 26, 480–486. [Google Scholar] [CrossRef] [Green Version]
- Vestbo, J.; Hurd, S.S.; Agusti, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187, 347–365. [Google Scholar] [CrossRef]
- Marchand, E.; Gayan-Ramirez, G.; De Leyn, P.; Decramer, M. Physiological basis of improvement after lung volume reduction surgery for severe emphysema: Where are we? Eur. Respir. J. 1999, 13, 686–696. [Google Scholar] [CrossRef] [Green Version]
- Martinez, F.J.; de Oca, M.M.; Whyte, R.I.; Stetz, J.; Gay, S.E.; Celli, B.R. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am. J. Respir. Crit. Care Med. 1997, 155, 1984–1990. [Google Scholar] [CrossRef]
- Criner, G.J.; Delage, A.; Voelker, K.; Hogarth, D.K.; Majid, A.; Zgoda, M.; Lazarus, D.R.; Casal, R.; Benzaquen, S.B.; Holladay, R.C.; et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am. J. Respir. Crit. Care Med. 2019, 200, 1354–1362. [Google Scholar] [CrossRef]
- Zhai, R.; Yu, X.; Shafer, A.; Wain, J.C.; Christiani, D.C. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 2014, 145, 346–353. [Google Scholar] [CrossRef] [Green Version]
- Sigel, K.; Kong, C.Y.; Rehmani, S.; Bates, S.; Gould, M.; Stone, K.; Kale, M.; Park, Y.-H.; Crothers, K.; Bhora, F.; et al. Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities. PLoS ONE 2021, 16, e0248067. [Google Scholar] [CrossRef]
- Cukic, V. Preoperative prediction of lung function in pneumonectomy by spirometry and lung perfusion scintigraphy. Acta Inform. Med. 2012, 20, 221–225. [Google Scholar] [CrossRef] [Green Version]
- British Thoracic Society. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001, 56, 89–108. [Google Scholar] [CrossRef] [Green Version]
- Kushibe, K.; Kawaguchi, T.; Kimura, M.; Takahama, M.; Tojo, T.; Taniguchi, S. Exercise capacity after lobectomy in patients with chronic obstructive pulmonary disease. Interact. Cardiovasc. Thorac. Surg. 2008, 7, 398–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raviv, S.; Hawkins, K.A.; DeCamp, M.M., Jr.; Kalhan, R. Lung cancer in chronic obstructive pulmonary disease: Enhancing surgical options and outcomes. Am. J. Respir. Crit. Care Med. 2011, 183, 1138–1146. [Google Scholar] [CrossRef]
- Birim, O.; Kappetein, A.P.; van Klaveren, R.J.; Bogers, A.J. Prognostic factors in non-small cell lung cancer surgery. Eur. J. Surg. Oncol. 2006, 32, 12–23. [Google Scholar] [CrossRef]
- Sengul, A.T.; Sahin, B.; Celenk, C.; Basoglu, A. Postoperative lung volume change depending on the resected lobe. Thorac. Cardiovasc. Surg. 2013, 61, 131–137. [Google Scholar] [CrossRef] [PubMed]
- Lugg, S.T.; Tikka, T.; Agostini, P.J.; Kerr, A.; Adams, K.; Kalkat, M.S.; Steyn, R.S.; Rajesh, P.B.; Bishay, E.; Thickett, D.R.; et al. Smoking and timing of cessation on postoperative pulmonary complications after curative-intent lung cancer surgery. J. Cardiothorac. Surg. 2017, 12, 52. [Google Scholar] [CrossRef] [Green Version]
- Heo, J.W.; Kang, H.S.; Park, C.K.; Kim, S.K.; Kim, J.S.; Kim, J.W.; Kim, S.J.; Lee, S.H.; Yeo, C.D. Regional emphysema score is associated with tumor location and poor prognosis in completely resected NSCLC patients. BMC Pulm. Med. 2020, 20, 242. [Google Scholar] [CrossRef]
- Wu, C.F.; Fu, J.Y.; Yeh, C.J.; Liu, Y.H.; Hsieh, M.J.; Wu, Y.C.; Wu, C.Y.; Tsai, Y.H.; Chou, W.C. Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer. Medicine 2015, 94, e1337. [Google Scholar] [CrossRef]
- Goldstraw, P.; Chansky, K.; Crowley, J.; Rami-Porta, R.; Asamura, H.; Eberhardt, W.E.; Nicholson, A.G.; Groome, P.; Mitchell, A.; Bolejack, V.; et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 2016, 11, 39–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ban, W.; Lee, J.M.; Ha, J.H.; Yeo, C.D.; Kang, H.H.; Rhee, C.K.; Moon, H.S.; Lee, S.H. Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer. Yonsei Med. J. 2016, 57, 1063. [Google Scholar] [CrossRef]
- Albuquerque, A.L.; Nery, L.E.; Villaca, D.S.; Machado, T.Y.; Oliveira, C.C.; Paes, A.T.; Neder, J.A. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur. Respir. J. 2006, 28, 939–944. [Google Scholar] [CrossRef] [Green Version]
- Shin, T.R.; Oh, Y.M.; Park, J.H.; Lee, K.S.; Oh, S.; Kang, D.R.; Sheen, S.; Seo, J.B.; Yoo, K.H.; Lee, J.H.; et al. The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease. J. Korean Med. Sci. 2015, 30, 1459–1465. [Google Scholar] [CrossRef] [Green Version]
- Choong, C.K.; Meyers, B.F.; Battafarano, R.J.; Guthrie, T.J.; Davis, G.E.; Patterson, G.A.; Cooper, J.D. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J. Thorac. Cardiovasc. Surg. 2004, 127, 1323–1331. [Google Scholar] [CrossRef] [Green Version]
- Seok, Y.; Cho, S.; Lee, J.Y.; Yang, H.C.; Kim, K.; Jheon, S. The effect of postoperative change in bronchial angle on postoperative pulmonary function after upper lobectomy in lung cancer patients. Interact. Cardiovasc. Thorac. Surg. 2014, 18, 183–188. [Google Scholar] [CrossRef] [Green Version]
- Sundaramoorthi, T.; Hashim, S.; Dillon, P.; Ramachandra, R.; Collins, F.J.; Rosin, M.D. An unusual cause of breathlessness after lobectomy for lung cancer. Ann. Thorac. Surg. 2004, 78, e13–e14. [Google Scholar] [CrossRef]
- Kang, N.; Shin, S.H.; Noh, J.M.; Kang, D.; Kim, H.; Kwon, O.J.; Pyo, H.; Ahn, Y.C.; Kim, H.K.; Choi, Y.S.; et al. Treatment modality and outcomes among early-stage non-small cell lung cancer patients with COPD: A cohort study. J. Thorac. Dis. 2020, 12, 4651–4660. [Google Scholar] [CrossRef]
- Sancheti, M.S.; Melvan, J.N.; Medbery, R.L.; Fernandez, F.G.; Gillespie, T.W.; Li, Q.; Binongo, J.N.; Pickens, A.; Force, S.D. Outcomes After Surgery in High-Risk Patients With Early Stage Lung Cancer. Ann. Thorac. Surg. 2016, 101, 1043–1050, Discussion 1051. [Google Scholar] [CrossRef] [Green Version]
- Kozower, B.D.; Sheng, S.; O’Brien, S.M.; Liptay, M.J.; Lau, C.L.; Jones, D.R.; Shahian, D.M.; Wright, C.D. STS database risk models: Predictors of mortality and major morbidity for lung cancer resection. Ann. Thorac. Surg. 2010, 90, 875–881, discussion 881–873. [Google Scholar] [CrossRef]
- Brunelli, A.; Charloux, A.; Bolliger, C.T.; Rocco, G.; Sculier, J.P.; Varela, G.; Licker, M.; Ferguson, M.K.; Faivre-Finn, C.; Huber, R.M.; et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur. Respir. J. 2009, 34, 17–41. [Google Scholar] [CrossRef] [Green Version]
- Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.; Chirieac, L.R.; D’Amico, T.A.; DeCamp, M.M.; Dilling, T.J.; Dobelbower, M.; et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2017, 15, 504–535. [Google Scholar] [CrossRef]
Figure 1.
Correlation of difference with (a) RV/TLC and (b) FEV1/FVC.
Table 1.
Clinical characteristics of the study patients.
| Overall Patients (n = 238) | |
|---|---|
| Age, years, mean ± SD | 66.7 ± 8.9 |
| Sex, n (%) | |
| Male | 144 (60.5) |
| Female | 94 (39.5) |
| ECOG performance status, n (%) | |
| 0 and 1 | 236 (99.2) |
| ≥2 | 2 (0.8) |
| Histologic features, n (%) | |
| Adenocarcinoma | 166 (69.7) |
| Squamous cell carcinoma | 55 (23.1) |
| Others | 17 (7.1) |
| Smoking, n (%) | |
| Never smoker | 94 (39.5) |
| Ever smoker | 144 (60.5) |
| Stage, n (%) | |
| I | 159 (66.8) |
| II | 49 (20.6) |
| III | 30 (12.6) |
| Location, n (%) | |
| RUL | 64 (26.9) |
| RML | 14 (5.9) |
| RLL | 48 (20.2) |
| LUL | 70 (29.4) |
| LLL | 42(17.6) |
| PFT | |
| FEV1 (pre), %, mean ± SD | 97.8 ± 21.5 |
| FEV1/FVC, %, mean ± SD | 73.2 ± 9.5 |
| DLco, %, mean ± SD | 88.2 ± 19.1 |
| RV/TLC, %, mean ± SD | 35.9 ± 8.7 |
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; PFT, pulmonary function test; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; RV, residual volume; TLC, total lung capacity.
Table 2.
Comparison between the FEV1 non-preserved and preserved groups.
| POD 6 Months (n = 238) | |||
|---|---|---|---|
| FEV1 Non-Preserved n = 74 (31.1%) | FEV1 Preserved n = 164 (68.9%) | p-Value | |
| Age, years, mean ± SD | 66.0 ± 8.6 | 67.0 ± 9.0 | 0.44 |
| Sex, n (%) | 0.73 | ||
| Male | 46 (61.1) | 98 (59.8) | |
| Female | 28 (37.8) | 66 (40.2) | |
| ECOG performance status, n (%) | 0.56 | ||
| 0 and 1 | 73 (98.6) | 163 (99.4) | |
| ≥2 | 1 (1.4) | 1 (0.6) | |
| Histologic features, n (%) | 0.09 | ||
| Sqcc | 12 (16.2) | 43 (26.2) | |
| Non-Sqcc | 62 (83.8) | 121 (73.8) | |
| Smoking, n (%) | 0.52 | ||
| Never | 27 (36.5) | 67 (40.9) | |
| Ever | 47 (63.5) | 97 (59.1) | |
| Stage, n (%) | 0.64 | ||
| I | 51 (68.9) | 108 (65.9) | |
| II–III | 23 (31.1) | 56 (34.1) | |
| Location, n (%) | 0.16 | ||
| BUL | 47 (63.5) | 88 (53.7) | |
| Others | 27 (36.5) | 76(46.3) | |
| Preoperative PFT | |||
| FEV1, %, mean ± SD | 100.2 ± 19.8 | 96.7 ± 22.2 | 0.24 |
| FEV1/FVC, %, mean ± SD | 74.1 ± 8.9 | 72.8 ± 9.8 | 0.34 |
| DLco, %, mean ± SD | 89.1 ± 17.7 | 87.8 ± 20.9 | 0.64 |
| RV/TLC ≥ 40%, n (%) | 15 (21.4) | 57 (36.1) | 0.03 |
POD, post-operative days; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; Sqcc, squamous cell carcinoma; BUL, both upper lobe; PFT, pulmonary function test; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; RV, residual volume; TLC, total lung capacity.
Table 3.
Factors associated with preserved postoperative FEV1.
| POD 6 Months (n = 238) | ||||||
|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||||
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
| Age | 1.01 | 0.98–1.04 | 0.434 | |||
| Sex (Female vs. Male) | 1.11 | 0.63–1.94 | 0.725 | |||
| ECOG (≥2 vs. 0–1) | 0.45 | 0.03–7.26 | 0.572 | |||
| Histology (Sqcc vs. Non-sqcc) | 1.84 | 0.90–3.73 | 0.093 | 1.42 | 0.68–2.97 | 0.357 |
| Smoking (Ever vs. Never) | 0.83 | 0.47–1.46 | 0.524 | |||
| Stage (II–III vs. I) | 1.15 | 0.64–2.07 | 0.642 | |||
| Location (BUL vs. other) | 0.67 | 0.38–1.17 | 0.157 | 0.68 | 0.38–1.22 | 0.199 |
| Preoperative FEV1 (<80% vs. ≥80%) | 1.50 | 0.71–3.15 | 0.287 | |||
| Preoperative FEV1/FVC (<70% vs. ≥70%) | 1.05 | 0.57–1.95 | 0.871 | |||
| Preoperative DLco (<80% vs. ≥80%) | 1.19 | 0.66–2.16 | 0.565 | |||
| Preoperative RV/TLC (≥40% vs. <40%) | 2.11 | 1.09–4.06 | 0.026 | 2.02 | 1.03–3.97 | 0.041 |
POD, post-operative days; ECOG, Eastern Cooperative Oncology Group; Sqcc, squamous cell carcinoma; Ever, current and former; BUL, both upper lobe; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; RV, residual volume; TLC, total lung capacity.
Table 4.
Correlation of differences (postoperative FEV1 minus ppoFEV1) with preoperative PFT parameters and postoperative FEV1.
Table 4.
Correlation of differences (postoperative FEV1 minus ppoFEV1) with preoperative PFT parameters and postoperative FEV1.
| Preoperative Variables | POD 6 Months | ||||
|---|---|---|---|---|---|
| Univariate | Multivariate | ||||
| Β ± SE | p-Value | Β ± SE | Partial R2 | p-Value | |
| FEV1 | −0.091 ± 0.042 | 0.032 | −0.001 ± 0.057 | 0.000 | 0.986 |
| FEV1/FVC | −22.129 ± 9.463 | 0.020 | −15.280 ± 11.310 | 0.008 | 0.178 |
| DLCO | −0.050 ± 0.046 | 0.281 | −0.033 ± 0.051 | 0.003 | 0.513 |
| RV/TLC | 36.895 ± 10.505 | 0.001 | 33.051 ± 11.388 | 0.048 | 0.004 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Kwon, O.-B.; Yeo, C.-D.; Lee, H.-Y.; Kang, H.-S.; Kim, S.-K.; Kim, J.-S.; Park, C.-K.; Lee, S.-H.; Kim, S.-J.; Kim, J.-W. The Value of Residual Volume/Total Lung Capacity as an Indicator for Predicting Postoperative Lung Function in Non-Small Lung Cancer. J. Clin. Med. 2021, 10, 4159. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10184159
AMA Style
Kwon O-B, Yeo C-D, Lee H-Y, Kang H-S, Kim S-K, Kim J-S, Park C-K, Lee S-H, Kim S-J, Kim J-W. The Value of Residual Volume/Total Lung Capacity as an Indicator for Predicting Postoperative Lung Function in Non-Small Lung Cancer. Journal of Clinical Medicine. 2021; 10(18):4159. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10184159
Chicago/Turabian StyleKwon, Oh-Beom, Chang-Dong Yeo, Hwa-Young Lee, Hye-Seon Kang, Sung-Kyoung Kim, Ju-Sang Kim, Chan-Kwon Park, Sang-Haak Lee, Seung-Joon Kim, and Jin-Woo Kim. 2021. "The Value of Residual Volume/Total Lung Capacity as an Indicator for Predicting Postoperative Lung Function in Non-Small Lung Cancer" Journal of Clinical Medicine 10, no. 18: 4159. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10184159
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
